Counterparties stepping up before the numbers do: escalating committed demand the reported results don't yet show
The model's full reasoning — Q3 2017 call → NOWe need to determine if management describes a real escalation by paying counterparties that is already happening or committed, and that the reported results do not yet reflect it because it's only beginning. Let's scan the transcript for relevant statements. Key points: - Bobby mentions new products: Nurse Residency Pathway and OB Risk program. He says: "we’ve recently begun to market and sale some of those products. In fact, all six products have shown revenue and some sales orders in this quarter, which is great. Again, very small but a nice start." That's small, not a big step-up. - For OB Risk: "one of our largest customers in our entire customer base, selected our OB Risk program... for system-wide deployment in a multiyear agreement" and also "top five account renewed its enterprise-wide use of our core platform and it's an early renewal, about a one year early renewal and they added four years to that early year. So it's essentially a five year contract. And in the process, they added some additional new products, for example, the knowledge Q product." This sounds like a significant commitment from a large customer. But is it described as a step-up beyond prior level? Yes, they renewed early and added years and new products. That's a real escalation. - Does management say the reported results don't yet reflect this? Bobby says: "There’s a lot of exciting pieces to that part of equation as we move one of our largest accounts on our newer technologies." But does he explicitly say the numbers lag? He says "very small but a nice start" for the new products. For the OB Risk and renewal, he doesn't explicitly say the revenue hasn't started yet. However, he says "we’ve recently begun to market and sale some of those products" and "all six products have shown revenue and some sales orders in this quarter" - so they have some revenue, but it's small. The large customer's commitment is a multiyear agreement, but it's not clear if revenue has started. He says "we’re pretty excited because that helps us in the marketing" for Nurse Residency, and for OB Risk he says "selected our OB Risk program... for system-wide deployment in a multiyear agreement" - that sounds like a signed deal, but revenue recognition may be later.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
KOP · Q2 2018 → YESThe question is: Does management describe that counterparties (customers etc.) are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that reported results do not yet meaningfully reflect...**NO** The transcript does not describe any counterparties (customers, clients, partners, etc.) currently stepping up their commitment to a distinctly higher level of engagement beyond prior patterns in a way that is already occurring or committed now, with the reported results lagging because most of the benefit is still ahead. The closest item is the major box store converting its ground-contact treated wood program to Koppers’ patented MicroPro technology, planned for late fall with “little effect on the balance of 2018” and a “nice boost heading into 2019.
SCPH · Q3 2023 → YESThe question is: Does management describe that counterparties who pay the company are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that the reported results do not yet meaningfully ...YES The transcript shows management describing a clear escalation in payer commitments: a new unrestricted-access agreement with the largest closed IDN (over 8 million lives, fixed copay) and preferred formulary status with a major government retiree payer (adding 1.1 million lives). They explicitly note that direct IDN purchases were not meaningful in Q3 but will be “a meaningful part of our business” moving forward, especially in 2024, and that the new payer decisions “could positively impact FUROSCIX co-pays as early as the fourth quarter.
GFS · Q3 2021 → YESThe question is: Does management describe that counterparties (customers) are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that the reported results do not yet meaningfully reflect ...**YES** Management describes counterparties (customers) stepping up their commitment through new and expanded long-term agreements (LTAs) and prepayments/access fees, which have grown since the roadshow (from ~$2.5B to north of $3B, with additional $500M+ added post-roadshow) and now exceed $20B in forward revenues. This is framed as real escalation in committed business, with customers signing more agreements and prepaying for future capacity. The reported Q3 results ($1.7B revenue, $0.07 adjusted EPS) and Q4 guidance ($1.